ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,67%
Bitcoin
66 776,40
2,36%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) Actualités

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SNDX
DateHeureSourceTitreSymboleSociété
16/05/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
16/05/202422h03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/05/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/05/202422h05PR Newswire (US)Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of DirectorsNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/05/202413h00PR Newswire (US)Syndax Announces Participation at the Bank of America Securities 2024 Health Care ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202413h06PR Newswire (US)Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202413h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
03/05/202422h05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
01/05/202413h00PR Newswire (US)Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
10/04/202422h05PR Newswire (US)Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/04/202413h00PR Newswire (US)Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionNASDAQ:SNDXSyndax Pharmaceuticals Inc
28/03/202412h00PR Newswire (US)Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
26/03/202421h05PR Newswire (US)Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
18/03/202412h00PR Newswire (US)Syndax Announces Appointment of Steven Closter as Chief Commercial OfficerNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202423h28Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202423h21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202422h05PR Newswire (US)Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
26/02/202413h00PR Newswire (US)Syndax Announces Participation at Two Upcoming Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
20/02/202422h05PR Newswire (US)Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202418h50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202413h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
02/01/202422h05PR Newswire (US)Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
02/01/202413h00PR Newswire (US)Syndax Highlights Recent Updates and Anticipated 2024 MilestonesNASDAQ:SNDXSyndax Pharmaceuticals Inc
19/12/202322h16PR Newswire (US)Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/12/202323h29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
15/12/202305h07PR Newswire (US)Syndax Announces Pricing of $200 Million Public Offering of Common StockNASDAQ:SNDXSyndax Pharmaceuticals Inc
14/12/202322h00PR Newswire (US)Syndax Announces Proposed $150 Million Public Offering of Common StockNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/12/202318h00PR Newswire (US)Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/12/202313h30PR Newswire (US)Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination TrialsNASDAQ:SNDXSyndax Pharmaceuticals Inc
11/12/202312h33Business WireIncyte und Syndax präsentieren bei ASH-Plenarsitzung weitere Daten aus positiver AGAVE-201-Studie, die die Wirksamkeit von Axatilimab zeigen, einschließlich dauerhaftem Ansprechen bei chronischer Graft-versus-Host-KrankheitNASDAQ:SNDXSyndax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SNDX

Dernières Valeurs Consultées

AMEX
STGF
Merk Stagflation ETF
ASX
FXLKOC
COIN
BORINGGBP
BoringDAO
XE
ACUV
Amundi Index Solutions
USOTC
PTNYF
Parcelpal Logistics (PK)
TSXV
ACAP.P
Atlas One Capital
BIT
UC7PWZ
Unicredit Bank
LSE
13OS
Telecom It
USOTC
RBCN
Rubicon Technology (QB)
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés